ArticleBioactive materials2026
Manganese oxide nanozyme-loaded CO-releasing halloysite nanotubes for remodeling colonic immune, microbiota, and intestinal barrier homeostasis with concurrent pain relief in ulcerative colitis.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- CO-mediated restoration of mitochondrial redox homeostasis contributes to alleviating multiple programmed cell deaths in hepatic I/R injury.Redox biology · 2026Article
- Thiol-mediated ROS-responsive hydrogel with arginine-driven NO cascade for colitis treatment.Materials today. Bio · 2026Article
- Engineered microvesicle-mediated multimodal therapy resolves ulcerative colitis via synergistic immunoregulation, barrier restoration, and microbiota remodeling.Materials today. Bio · 2026Article
- Mucin armoured diethylaminoethyl-dextran cloaked rebamipide based oral nanoformulation for the therapy of inflammatory bowel disease.Materials today. Bio · 2026Article
- Orally administered biomimetic nanovesicles engineered with FGF2 orchestrate mucosal healing and microbiome remodeling in inflammatory bowel disease.Materials today. Bio · 2026Article
- Natural carrier-free self-assembled binary polyphenol nanoparticles remodel the gut microenvironment for inflammatory bowel disease prevention.Materials today. Bio · 2026Article
- Design of Single-Atom Nanozymes for Precision Treatment of Erectile Dysfunction with Integrated Single-Cell RNA Sequencing and Machine Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Inulin-Butyrate Nanogel for Modulation of Gut Microbiome, Intestinal Barrier, and Regulatory T-Cells in Colitis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Targeted intestinal barrier repairActa pharmaceutica Sinica. B · 2026Article
- Programmed Probiotics Generate Interleukin-37b-Bearing Nanovesicles In Situ for Precision Immunomodulation in Colitis.Research (Washington, D.C.) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) involves immune dysregulation, barrier dysfunction, and dysbiosis, driving chronic inflammation and pain. Current treatments show limited efficacy and high toxicity. This study develops an engineered nanozyme, CO&MnOx@Hs (CMHs), synthesized via in-situ manganese oxide (MnOx) generation on halloysite nanotubes (Hs) with controlled encapsulation of the carbon monoxide (CO)-releasing molecule CORM-401 for gas therapy. CMHs selectively accumulate at inflamed UC sites, where MnOx scavenges reactive oxygen species (ROS) while CO exerts anti-inflammatory effects. These combined actions restore immune homeostasis, repair intestinal barrier, modulate gut microbiota, and alleviate inflammation-associated pain. In murine ulcerative colitis, CMHs outperform conventional treatments, demonstrating superior therapeutic efficacy. Mechanistic studies reveal that CMHs activate Nrf2/HO-1 for antioxidant effects while modulating PI3K-Akt and HIF-1α/LDHA pathways to promote M2 macrophage polarization and suppress NF-κB/TNF signaling. CMHs also fortify the intestinal barrier by mitigating bacterial invasion and ROS-induced damage while activating focal adhesion and ECM-receptor interaction. 16S ribosomal RNA sequencing further confirms CMHs' ability to remodel gut microbiota, reinforcing their immunomodulatory potential. Importantly, CMHs relieve chronic pain by reducing inflammation, inhibiting SP secretion and TACR1 expression, and suppressing TRPV1 channel activation and Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.